JP7573967B2 - Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用 - Google Patents

Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用 Download PDF

Info

Publication number
JP7573967B2
JP7573967B2 JP2019540514A JP2019540514A JP7573967B2 JP 7573967 B2 JP7573967 B2 JP 7573967B2 JP 2019540514 A JP2019540514 A JP 2019540514A JP 2019540514 A JP2019540514 A JP 2019540514A JP 7573967 B2 JP7573967 B2 JP 7573967B2
Authority
JP
Japan
Prior art keywords
pdsp
cells
dry eye
pedf
corneal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019540514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533722A5 (enExample
JP2019533722A (ja
Inventor
フランク ウェン－チー リー
クァンユィン カレン リン
ヨウ－ピン ツァオ
ツォン‐チュアン ホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brim Biotechnology Inc
Original Assignee
Brim Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brim Biotechnology Inc filed Critical Brim Biotechnology Inc
Publication of JP2019533722A publication Critical patent/JP2019533722A/ja
Publication of JP2019533722A5 publication Critical patent/JP2019533722A5/ja
Priority to JP2022155973A priority Critical patent/JP2022185042A/ja
Application granted granted Critical
Publication of JP7573967B2 publication Critical patent/JP7573967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019540514A 2016-10-07 2017-08-24 Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用 Active JP7573967B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022155973A JP2022185042A (ja) 2016-10-07 2022-09-29 Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
US62/405,522 2016-10-07
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022155973A Division JP2022185042A (ja) 2016-10-07 2022-09-29 Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2019533722A JP2019533722A (ja) 2019-11-21
JP2019533722A5 JP2019533722A5 (enExample) 2020-10-01
JP7573967B2 true JP7573967B2 (ja) 2024-10-28

Family

ID=61831898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019540514A Active JP7573967B2 (ja) 2016-10-07 2017-08-24 Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用
JP2022155973A Pending JP2022185042A (ja) 2016-10-07 2022-09-29 Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022155973A Pending JP2022185042A (ja) 2016-10-07 2022-09-29 Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用

Country Status (10)

Country Link
US (1) US11760784B2 (enExample)
EP (1) EP3596104A4 (enExample)
JP (2) JP7573967B2 (enExample)
KR (2) KR20230169375A (enExample)
CN (1) CN110312732A (enExample)
AU (2) AU2017340245B2 (enExample)
EA (1) EA037698B1 (enExample)
IL (1) IL265796B2 (enExample)
TW (1) TWI878203B (enExample)
WO (2) WO2018067244A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277689B2 (en) * 2018-04-08 2024-12-01 Brim Biotechnology Inc Application of pedf-derived short peptides in tendon healing
US20210221862A1 (en) * 2018-04-08 2021-07-22 Brim Biotechnology, Inc. Application of pedf-derived short peptides in the treatment of osteoarthritis
EP3773493A4 (en) * 2018-05-04 2022-03-30 Brim Biotechnology, Inc. PEDF DERIVED PEPTIDES TO PROMOTE MEIBOMIUS GLAND REGENERATION AND THEIR USES
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
US12221494B2 (en) * 2019-08-27 2025-02-11 Mackay Memorial Hospital Short synthetic peptides and their uses for treating retinal degenerative diseases and/or tissue injuries
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
CN115151243A (zh) * 2019-10-06 2022-10-04 全福生物科技股份有限公司 包含pedf-衍生短肽(pdsp)的组合物及其用途
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途
KR20250023387A (ko) * 2022-06-13 2025-02-18 브림 바이오테크놀로지, 인코퍼레이티드 안구 건조증 질환 치료를 위한 pedf 유래 짧은 펩타이드를 포함하는 조성물
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150183832A1 (en) 2011-03-23 2015-07-02 Mackay Memorial Hospital Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
CN101014358A (zh) * 2003-10-29 2007-08-08 约翰·霍普金斯大学 色素上皮所衍生因子的生物活性及使用方法
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
US20090069241A1 (en) * 2006-02-15 2009-03-12 Yale University Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments
EP2271760A2 (en) * 2008-04-29 2011-01-12 Monsanto Technology LLC Genes and uses for plant enhancement
US20110111008A1 (en) * 2009-10-08 2011-05-12 Weng Tao Use of PEDF in an Encapsulated Cell-Based Delivery System
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
AU2012387503B2 (en) * 2012-08-09 2016-11-03 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
AU2012390200B2 (en) * 2012-09-19 2017-06-29 Mackay Memorial Hospital Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
WO2014043871A1 (en) * 2012-09-20 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for treating osteoarthritis
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150183832A1 (en) 2011-03-23 2015-07-02 Mackay Memorial Hospital Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing

Also Published As

Publication number Publication date
IL265796B2 (en) 2025-02-01
AU2022204557A1 (en) 2022-07-21
WO2018067217A2 (en) 2018-04-12
AU2017340245A1 (en) 2019-05-23
EA037698B1 (ru) 2021-05-12
IL265796B1 (en) 2024-10-01
CN110312732A (zh) 2019-10-08
EP3596104A4 (en) 2021-02-17
WO2018067217A3 (en) 2019-05-02
EA201990885A1 (ru) 2019-08-30
US20190248859A1 (en) 2019-08-15
AU2017340245B2 (en) 2022-07-21
US11760784B2 (en) 2023-09-19
TW201822785A (zh) 2018-07-01
KR20190066030A (ko) 2019-06-12
WO2018067244A1 (en) 2018-04-12
KR20230169375A (ko) 2023-12-15
JP2022185042A (ja) 2022-12-13
JP2019533722A (ja) 2019-11-21
TWI878203B (zh) 2025-04-01
IL265796A (en) 2019-06-30
EP3596104A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
JP7573967B2 (ja) Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用
JP6612247B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
US20240123032A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
Shi et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury
WO2022095765A1 (zh) 一种p55pik抑制剂在制备干眼治疗药物中的应用
TWI796875B (zh) 一種醫藥組合物用於製備眼表損傷之藥物的用途
JP2022542889A (ja) ドライアイ疾患のためのｔｓｇ６ポリペプチドフラグメント
JP2021523116A (ja) マイボーム腺再生を促進するためのｐｅｄｆ由来ペプチドおよびその使用
CN118717959A (zh) Pedf多肽模拟物在眼表疾病中的用途
JP2025181979A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
Kim et al. Protective Effects of Misgurnus mizolepis Protein Hydrolysate against Atropine-Induced Dry Eye Disease
WO2017049001A1 (en) Protection and sealing of the ocular surface barrier by clusterin
AU2019463840A1 (en) Short synthetic peptide and their uses for treating retinal degenerative diseases and/or tissue injuries
Fernandez-Robredo et al. Azithromycin reduces inflammation in a rat model of acute conjunctivitis
KR20180080310A (ko) 각막 장애의 치료를 위한 프로테아솜 조정

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220930

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221115

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221116

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221216

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241016

R150 Certificate of patent or registration of utility model

Ref document number: 7573967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150